Apotex Corp. announces the launch of brimonidine tartrate ophthalmic solution, 0.1% in the United States

Apotex Corp. has released its latest ophthalmic product in the United States, brimonidine tartrate ophthalmic solution, 0.1%, which is now available.

Brimonidine is an alpha-adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.¹

“Open-angle glaucoma impacts over 2.7 million Americans, and millions more have ocular hypertension. Bringing this product to market will make a real difference for these patients, who depend on this medicine to preserve their vision,” said Peter Hardwick, President, Apotex Corp. “We’re excited to be able to offer this high-quality, cost-saving option to prescribers and patients across the country.”¹

Earlier in the year, Apotex Corp. initiated a voluntary recall at the consumer level for 6 lots of brimonidine tartrate ophthalmic solution, 0.15% due to cracks that developed in some of the bottle caps.

References:

1. Apotex Corp. Launches Brimonidine Tartrate Ophthalmic Solution, 0.1% in the United States. Apotex Corp. Press Release. Released September 5, 2023. Accessed September 5, 2023. https://www.apotex.com/us/about-us/press-center/2023/09/05/apotex-corp.-launches-brimonidine-tartrate-ophthalmic-solution-0.1-in-the-united-states